Michael A O'Donnell

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

End Stage Renal Disease

Prognostic Factors

Muscle Invasive Bladder Cancer

Top Venues

BJU international

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamad Abou Chakra, Riitta Lassila, Nancy El Beayni, Sarah L Mott, Michael A O'Donnell
Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel. BJU international (2024)
Ian M McElree, Vignesh T Packiam, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Mohamad Abou Chakra, Yousef Zakharia, Michael A O'Donnell
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers 16 (14) (2024)
Ian M McElree, Vignesh T Packiam, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Mohamad Abou Chakra, Yousef Zakharia, Michael A O'Donnell
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers 16 (14) (2024)
Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Drupad Annapureddy, Jeffrey M Howard, Wei Shen Tan, Ian M McElree, Facundo Davaro, Kendrick Yim, Stephen Harrington, Elizabeth Dyer, Anna J Black, Pratik Kanabur, Mathieu Roumiguié, Seth Lerner, Peter C Black, Jay D Raman, Mark A Preston, Gary Steinberg, William Huang, Roger Li, Vignesh T Packiam, Solomon L Woldu, Yair Lotan
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU international (2024)
Ian M McElree, Vignesh T Packiam, Ryan L Steinberg, Helen Y Hougen, Sarah L Mott, Mohamad Abou Chakra, Yousef Zakharia, Michael A O'Donnell
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor. Cancers 16 (14) (2024)